The Role of Rivaroxaban in the Treatment of Patients with Stable Coronary Artery Disease
https://doi.org/10.21518/2079-701X-2019-16-34-41
Abstract
An analytical article discusses the design and results of the recent COMPASS study. Particular attention is paid to the details of comparison of the efficacy and safety of rivaroxaban combined with acetylsalicylic acid and the efficacy and safety of drugs containing acetylsalicylic acid only in patients with stable coronary artery disease. In addition to a significant reduction in the risk of the sum of traditionally recognizable events (myocardial infarction, stroke, cardiovascular mortality), among the arguments in favour of fairly widespread prolonged use of the antiplatelet agent combined with anticoagulant is an attractive effect of the debated antithrombotic strategy on the overall mortality of patients, an acceptable ratio of efficacy and hemorrhagic safety, first of all the absence of the increased risk of fatal bleeding and the risk of intracranial bleeding. The article describes approaches to the selection of patients with coronary artery disease for the participation in the long-term treatment with rivaroxaban combined with acetylsalicylic acid. Alternative possibilities for enhancement of the secondary prophylactic effects of acetylsalicylic acid are mentioned, the arguments supporting the preference of the approach discussed in the article are presented.
About the Author
O. V. Averkov
Municipal Clinical Hospital No. 15 named after О.М. Filatov;
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Oleg V. Averkov, Dr. of Sci. (Med.), Deputy Chief Physician, Head of Regional Vascular Center, State Budgetary Healthcare Institution
Professor, Chair for Hospital Therapy No. 1 at Medical Faculty
References
1. Libby P. Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111:3481– 3488. doi: 10.1161/ CIRCULATIONAHA.105.537878.
2. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-2381. doi: 10.1093/eurheartj/ ehw106.
3. Alberts M.J., Bhatt D.L., Mas J.L., Ohman E.M., Hirsch A.T., Röther J., Salette G., Goto S., Smith Jr.S.C., Chiau-Suong Liau, Wilson P.W.F., Steg Ph. G. REduction of Atherothrombosis for Continued Health Registry Investigators. Threeyear follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J. 2009;30(19):2318-2326. doi: 10.1093/eurheartj/ ehp355.
4. Bhatt D.L., Flather M.D., Hacke W., Berger P.B., Black H.R., Boden W.E., Cacoub P., Cohen E.A., Creager M.A., Easton J.D., Hamm C.W., Hankey G.J., Johnston S.C., Mak K.H., Mas J.L., Montalescot G., Pearson T.A., Steg P.G., Steinhubl S.R., Weber M.A., Fabry-Ribaudo L., Hu T., Topol E.J., Fox K.A. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;(49):1982-1988. doi: 10.1016/j.jacc.2007.03.025.
5. Bonaca M.P., Bhatt D.L., Storey R.F., Steg P.G., Cohen M., Kuder J., Goodrich E., Nicolau J.C., Parkhomenko A., López-Sendón J., Dellborg M., Dalby A., Špinar J., Aylward P., Corbalán R., Abola M.T.B., Jensen E.C., Held P., Braunwald E., Sabatine M.S. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2016;67(23):2719-2728. doi:10.1016/j.jacc.2016.03.524.
6. Morrow D. A., Braunwald E., Bonaca M.P., Ameriso S.F., Dalby A.J., Fish M.P., Fox K.A., Lipka L.J., Liu X., Nicolau J.C., Ophuis A.J., Paolasso E., Scirica B.M., Spinar J., Theroux P., Wiviott S.D., Strony J., Murphy S.A. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;(366):1404-1413. doi: 10.1056/NEJMoa1200933.
7. Bosch J., Eikelboom J.W., Connolly S.J., Bruns N.C., Lanius V., Yuan F., Misselwitz F., Chen E., Diaz R., Alings M., Lonn E.M., Widimsky P., Hori M., Avezum A., Piegas L.S., Bhatt D.L., Branch K.R.H., Probstfield J.L., Liang Y., Liu L., Zhu J., Maggioni A.P., Lopez-Jaramillo P., O’Donnell M., Fox K.A.A., Kakkar A., Parkhomenko A.N., Ertl G., Störk S., Keltai K., Keltai M., Ryden L., Dagenais G.R., Pogosova N., Dans A.L., Lanas F., Commerford P.J., Torp-Pedersen C., Guzik T.J., Verhamme P.B., Vinereanu D., Kim J.-H., Ha J.-W., Tonkin A.M., Varigos J.D., Lewis B.S., Felix C., Yusoff K., Steg P.G., Aboyans V., Metsarinne K.P., Anand S.S., Hart R.G., Lamy A., Moayyedi P., Leong D.P., Sharma, Yusuf S. Rationale, design and baseline characteristics of participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial. Can J Cardiol. 2017;33(8):1027-1035. doi: 10.1016/j. cjca.2017.06.001.
8. Eikelboom J.W., Connolly S.J., Bosch J. Dagenais G.R., Hart R.G., Shestakovska O., Diaz R., Alings M., Lonn E.M., Anand S.S., Widimsky P., Hori M., Avezum A., Piegas L.S., Branch K.R.H., Probstfield J., Bhatt D.L., Zhu J., Liang Y., Maggioni A.P., Lopez-Jaramillo P., O’Donnell M., Kakkar A.K., Fox K.A.A., Parkhomenko A.N., Ertl G., Störk S., Keltai M., Ryden L., Pogosova N., Dans A.L., Lanas F., Commerford P.J., Torp-Pedersen C., Guzik T.J., Verhamme P.B., Vinereanu D., Kim J.H., Tonkin A.M., Lewis B.S., Felix C., Yusoff K., Steg P.G., Metsarinne K.P., Cook Bruns N., Misselwitz F., Chen E., Leong D., Yusuf S. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;(377):1319-1330. doi: 10.1056/NEJMoa1709118.
9. Anand S.S., Bosch J., Eikelboom J.W., Connolly S.J., Diaz R., Widimsky P., Aboyans V., Alings M., Kakkar A.K., Keltai K., Maggioni A.P., Lewis B.S., Störk S., Zhu J., Lopez-Jaramillo P., O’Donnell M., Commerford P.J., Vinereanu D., Pogosova N., Ryden L., Fox K.A.A., Bhatt D.L., Misselwitz F., Varigos J.D., Vanassche T., Avezum A.A., Chen E., Branch K., Leong D.P., Bangdiwala S.I., Hart R.G., Yusuf S. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomized, double-blind, placebo-controlled trial. Lancet. 2018;(391):219–229. doi: 10.1016/S0140- 6736(17)32409-1.
10. Connolly S.J., Eikelboom J.W., Bosch J., Dagenais G., Dyal L., Lanas F., Metsarinne K., O’Donnell M., Dans A.L., Ha J.W., Parkhomenko A.N., Avezum A.A., Lonn E., Lisheng L., Torp-Pedersen C., Widimsky P., Maggioni A.P., Felix C., Keltai K., Hori M., Yusoff K., Guzik T.J., Bhatt D.L., Branch K.R.H., Cook Bruns N., Berkowitz S.D., Anand S.S., Varigos J.D., Fox K.A.A., Yusuf S. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomized, double-blind, placebo-controlled trial. Lancet. 2018;(391):205–218. doi: 10.1016/S0140-6736(17)32458-3.
11. Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Brentano C., Prescott E., Storey R.F., Deaton C., Cuisset T., Agewall S., Dickstein K., Edvardsen T., Escaned J., Gersh B.J., Svitil P., Gilard M., Hasdai D., Hatala R., Mahfoud F., Masip J., Muneretto C., Valgimigli M., Achenbach S., Bax J.J., ESC Scientific Document Group, 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal. 2019:ehz425. doi: 10.1093/eurheartj/ehz425.
12. Darmon A., Bhatt D.L., Elbez Y., Aboyans V., Anand S., Bosch J., Branch K.R., Connolly S.J., Dyal L., Eikelboom J.W., Fox K.A.A., Keltai K., Probstfield J., Yusuf S., Abtan J., Sorbets E., Eagle K.A., Ducrocq G., Steg P.G. External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. Eur Heart J. 2018;39(9):750- 757a. doi: 10.1093/eurheartj/ehx658.
Review
For citations:
Averkov OV. The Role of Rivaroxaban in the Treatment of Patients with Stable Coronary Artery Disease. Meditsinskiy sovet = Medical Council. 2019;(16):34-41. (In Russ.) https://doi.org/10.21518/2079-701X-2019-16-34-41
Views:
622
Email this article 